Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 18/20 | 0.59 |
| ▸ | KMO | O15229 | 1/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 6/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1398555 | 0.92 | S1PR1 (0.58) | S1PR1S1PR5S1PR3S1PR4 | |
| SCHEMBL1398473 | 0.90 | S1PR1 (0.48) | S1PR1S1PR5S1PR3S1PR4 | |
| SCHEMBL1398423 | 0.87 | S1PR1 (0.66) | S1PR1KMOS1PR5S1PR3S1PR4 | |
| SCHEMBL1398654 | 0.86 | S1PR1 (0.50) | S1PR1S1PR3 | |
| SCHEMBL1398474 | 0.84 | S1PR1 (0.59) | S1PR1KMO | |
| SCHEMBL1398514 | 0.80 | S1PR1 (0.53) | S1PR1S1PR5S1PR3 | |
| SCHEMBL1398511 | 0.79 | S1PR1 (0.55) | S1PR1S1PR5S1PR3S1PR4 | |
| SCHEMBL12809021 | 0.78 | S1PR1 (0.59) | S1PR1KMOS1PR3NR1H4 | |
| SCHEMBL399929 | 0.77 | S1PR1 (0.60) | S1PR1S1PR5S1PR3S1PR4 | |
| SCHEMBL1398626 | 0.76 | S1PR1 (0.59) | S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324254-B2 | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists | GLAXO GROUP LIMITED (GB) | 2012-12-04 | — | — | US | claimed |
| US-20100113528-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS | GLAXO GROUP LIMITED | 2010-05-06 | — | — | US | claimed |
| CN-101663297-A | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists | GLAXO GROUP LTD | 2010-03-03 | — | — | CN | claimed |
| CN-101663297-B | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists | GLAXO GROUP LTD | 2013-05-08 | — | — | CN | disclosed |
| US-8324254-B2 | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists | GLAXO GROUP LIMITED (GB) | 2012-12-04 | — | — | US | disclosed |
| US-8324254-B2 | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists | GLAXO GROUP LIMITED (GB) | 2012-12-04 | — | — | US | disclosed |
| US-8324254-B2 | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists | GLAXO GROUP LIMITED (GB) | 2012-12-04 | — | — | US | disclosed |
| EP-2137181-B1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS | GLAXO GROUP LTD (GB) | 2011-03-02 | — | — | EP | disclosed |
| EP-2137181-B1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS | GLAXO GROUP LTD (GB) | 2011-03-02 | — | — | EP | disclosed |
| US-20100113528-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS | GLAXO GROUP LIMITED | 2010-05-06 | — | — | US | disclosed |
| US-20100113528-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS | GLAXO GROUP LIMITED | 2010-05-06 | — | — | US | disclosed |
| US-20100113528-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS | GLAXO GROUP LIMITED | 2010-05-06 | — | — | US | disclosed |
| CN-101663297-A | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists | GLAXO GROUP LTD | 2010-03-03 | — | — | CN | disclosed |
| EP-2137181-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS | Glaxo Group Limited (GB) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008128951-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008128951-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113528-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885KMO 2310/4885S1PR5 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.